The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

Medscape Medical News, March 31, 2025 ACC 2025 Oral GLP-1 Receptor Agonist Reduces CV Risk Oral semaglutide ... enhance the early detection of chronic kidney disease in low-risk patients, a ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

The SOUL trial compared oral semaglutide vs. placebo on top of standard care in patients with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both.

Semaglutide increased maximum walking distance ... end-stage kidney disease and cardiovascular death in adults with T2D and chronic kidney disease.

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

One study found that semaglutide helps to improve ... excluded participants who had other chronic liver problems besides nonalcoholic fatty liver disease. Other exclusion criteria included ...